Patent Infringement by ANDA Filing
Courts are in general designed to adjudicate past events (e.g., crimes and torts which have already occurred). Thus, for example, proving patent infringement merely requires showing the court the on-market product, and comparing it to the patent at issue. United States law, however, provides for a fundamentally-different kind of infringement: potential future infringement by a future generic pharmaceutical product which does not yet exist because it has not yet been approved for marketing. This type of infringement requires U.S. courts to adjudicate future events, predicting the likely characteristics of the future generic pharmaceutical. In requiring a court to adjudicate a potential future event, this type of infringement can pose a unique evidentiary challenge to judges. This article discusses how U.S. judges evaluate potential future infringement by generic pharmaceuticals.
Generic drug; generic pharmaceutical; ANDA; Abbreviated New Drug Application; infringement; patent infringement; artificial infringement; Hatch-Waxman; pharmaceutical patent infringement.
Full Text: PDF (downloaded 198 times)
- There are currently no refbacks.